Numinus Wellness has announced that it has advanced to the next implementation phase in the clinical trial “A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX)” sponsored by the MAPS and organized by MAPS PBC by enrolling and dosing the first clinical trial volunteer in Canada.
Category Press Release
Published in Cision Newswire
Companies Featured
NuminusNuminus is a Canadian company trying to create a platform for the therapeutic use of psychedelics. Working together with researchers, yet also wanting to see how to make it commercially viable. The two founders both came here from personal experiences.
MAPS
MAPS stands for Multidisciplinary Association for Psychedelic Studies, it's the front runner in making psychedelics a legal way to use (and improve) in therapy.
Trials Linked
A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSDThis multi-site open-label study assesses the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in participants who were enrolled in a parent study for the treatment of posttraumatic stress disorder (PTSD).